Literature DB >> 15858616

Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.

C Gambacorti-Passerini, M Gasser, S Ahmed, S Assouline, L Scapozza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15858616     DOI： 10.1038/sj.leu.2403775

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

Review 1.  The second generation of BCR-ABL tyrosine kinase inhibitors.

Authors:  Tetsuzo Tauchi; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

2.  The IgE-dependent pathway in allergic transfusion reactions: involvement of donor blood allergens other than plasma proteins.

Authors:  Nobuki Matsuyama; Kazuta Yasui; Etsuko Amakishi; Tomoya Hayashi; Ayumu Kuroishi; Hiroyuki Ishii; Harumichi Matsukura; Yoshihiko Tani; Rika A Furuta; Fumiya Hirayama
Journal:  Int J Hematol       Date:  2015-04-04       Impact factor: 2.490

Review 3.  Metabolism considerations for kinase inhibitors in cancer treatment.

Authors:  Derek R Duckett; Michael D Cameron
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

4.  Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.

Authors:  Lina Han; Jan Jacob Schuringa; André Mulder; Edo Vellenga
Journal:  Ann Hematol       Date:  2010-04-13       Impact factor: 3.673

5.  Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.

Authors:  Xiaohai Li; Yuanjun He; Claudia H Ruiz; Marcel Koenig; Michael D Cameron; Tomas Vojkovsky
Journal:  Drug Metab Dispos       Date:  2009-03-12       Impact factor: 3.922

6.  Identification of common inhibitors of wild-type and T315I mutant of BCR-ABL through the parallel structure-based virtual screening.

Authors:  Hwangseo Park; Seunghee Hong; Sungwoo Hong
Journal:  J Comput Aided Mol Des       Date:  2012-08-11       Impact factor: 3.686

7.  Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments.

Authors:  Erik Laurini; Paola Posocco; Maurizio Fermeglia; Don L Gibbons; Alfonso Quintás-Cardama; Sabrina Pricl
Journal:  Mol Oncol       Date:  2013-06-15       Impact factor: 6.603

8.  Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.

Authors:  Yusuf Baran; Guray Saydam
Journal:  J Blood Med       Date:  2012-11-16

Review 9.  The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Authors:  Taira Maekawa; Eishi Ashihara; Shinya Kimura
Journal:  Int J Clin Oncol       Date:  2007-10-22       Impact factor: 3.850

10.  Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.

Authors:  J Chen; A Schmitt; B Chen; M Rojewski; V Rübeler; F Fei; Y Yu; X Yu; M Ringhoffer; S von Harsdorf; J Greiner; M Götzz; P Guillaume; H Döhner; D Bunjes; M Schmitt
Journal:  J Cell Mol Med       Date:  2008-01-11       Impact factor: 5.310
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.